COMMUNIQUÉS West-GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
14/11/2025
– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment [...]
Biogen Completes Acquisition of Alcyone Therapeutics
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
4DMT Announces New Employment Inducement Grants
14/11/2025
EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
14/11/2025
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular [...]
Health Catalyst to Participate in Upcoming Investor Conferences
14/11/2025
SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]
PetVivo Reports Fiscal Q2 2026 Results with Revenues up 50%
14/11/2025
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative [...]
Precipio Announces its Q3-2025 Financial Results
14/11/2025
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its [...]
BiomX Inc. Announces 1-for-19 Reverse Stock Split
14/11/2025
NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific [...]
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
14/11/2025
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
Avadel Receives Unsolicited Proposal from Lundbeck
14/11/2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION [...]
New study finds half of young men at risk of problem anger
14/11/2025
VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- New research from the Canadian Men’s Health Foundation (CMHF) reveals half of Canadian men aged 19–29 are at risk of problem anger—when anger interferes [...]
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
14/11/2025
Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10 [...]
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14/11/2025
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes [...]
Orion receives award for international growth from the President of the Republic of Finland
14/11/2025
ORION CORPORATION PRESS RELEASE 14 NOVEMBER 2025 at 13.30 EET Orion receives award for international growth from the President of the Republic of Finland Today, the President of the Republic of Finland, Alexander Stubb [...]
Teleflex to Present at the Jefferies Global Healthcare Conference in London
14/11/2025
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. ( [...]
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
14/11/2025
Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc. Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate [...]
Picard Reports Third Quarter 2025 Financial Results
14/11/2025
– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of [...]
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
14/11/2025
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin [...]

Pages